1-7 of 7
Xingchen Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China

Free
Honghan Qiao, Xingchen Liu, Huijie Nan, Mingzhi Zhang, Yanliang Bai, Keshu Zhou, Xudong Zhang
Journal: Blood
Blood (2025) 146 (Supplement 1): 7206.
https://doi.org/10.1182/blood-2025-7206
Published: 2025
Journal Articles

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

Free
Qing Zhang, Yi Wu, Xueli Jiao, Qinglan Zhang, Xingchen Liu, Fenghua Gao, Hao Guo, Zhanfang Wang, quande Lin, Shuli Guo, Fengkuan Yu, Jianwei Du, Lihua Dong, Hu Zhou, Ping Wang, Yuqing Chen, Yan Huang, Yan Zhao, Hongmian Zhao, Xiujuan Zhao, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 1823.
https://doi.org/10.1182/blood-2025-1823
Published: 2025
Journal Articles

The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Free
Keshu Zhou, Xingchen Liu, Xueli Jiao, Qing Zhang, xu Ji, Qianying Pan, Kai Hu, Bian Wei, Lin Chen, Fenghua Gao, Minghui Li, Quande Lin, Ruihua Mi, Fengdi Wang, Haiying Wang, Qinglan Zhang, Lihua Dong
Journal: Blood
Blood (2025) 146 (Supplement 1): 1914.
https://doi.org/10.1182/blood-2025-1914
Published: 2025
Journal Articles

Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study

Free
Xingchen Liu, Qing Zhang, Hao Guo, Qianying Pan, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 1847.
https://doi.org/10.1182/blood-2025-1847
Published: 2025
Journal Articles

Efficacy and safety of polatuzumab vedotin-based regimens for elderly/frail DLBCL patients: A real-world study

Free
Xingchen Liu, Qing Zhang, Qianying Pan, Xueli Jiao, Fenghua Gao, Lihua Dong, Zhihua Yao, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 5470.
https://doi.org/10.1182/blood-2025-5470
Published: 2025
Journal Articles

IMM01 Plus Tislelizumab in Prior Anti-PD-1 Failed Classic Hodgkin Lymphoma: An Open Label, Multicenter, Phase 2 Study (IMM01-04) Evaluating Safety As Well As Preliminary Anti-Tumor Activity

Free
Keshu Zhou, Yuqin Song, Tienan Yi, Shuling Hou, Xingchen Liu, Ningjing Lin, Tingting Du, Xing Zhao, Xiaobo Wu, Xiwen Zhao, Wei Meng, Wencheng Xu, Qiying Lu, Wenzhi Tian, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 609.
https://doi.org/10.1182/blood-2023-174829
Published: 2023
Journal Articles

CoupledCAR TM Technology for Treating Thyroid Cancer

Free
Xingchen Liu, Lei Xiao, PhD, Keshu Zhou, Yu Liu, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 46.
https://doi.org/10.1182/blood-2020-138668
Published: 2020